ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

About this update from Alnylam Pharmaceuticals, Inc.

Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies and expanding regulatory approvals across multiple rare diseases enhance market penetration. Its strong sales growth and expansion into neurology and nephrology further solidify its position. Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Recent phase III data showcased ULTOMIRIS's efficacy in pediatric TMA post stem cell transplantation, with an 87.2% survival rate. The "ULTOMIRIS Sales Forecast, and Market Size Analysis - 2034" report provides insightful forecasts and market positioning, coupled with competitive intelligence and regulatory landscapes. ULTOMIRIS Drug Summary ULTOMIRIS (Ravulizumab), developed by Alexion (AstraZeneca), is a monoclonal antibody that inhibits complement C5. Indicated for PNH, aHUS, NMOSD, and gMG, it enhances patient outcomes by binding to C5 to prevent cleavage into pro-inflammatory compounds, offering sustained inhibition with long dosing intervals. Though associated with a risk of serious infections, necessitating vaccination, its broader implication in treating rare diseases cements its market position. ULTOMIRIS Analytical Perspective and Clinical Assessment This section covers ULTOMIRIS's market assessment, sales data, competitive intelligence, and clinical trials information for approved and potential indications, along with strategic insights into pricing and reimbursement across geographies. Key Factors Driving ULTOMIRIS Growth Long-Acting C5 Inhibition With Significant Convenience Advantage ULTOMIRIS, engineered from eculizumab, provides sustained complement blockade with fewer infusions, marked by intravenous dosing once every 8 weeks as opposed to every 2 weeks for earlier therapies. This extended dosing interval greatly reduces treatment burden and facilitates improved compliance, encouraging the switch from older inhibitors and boosting market penetration. Rapid Conversion From Earlier Complement Therapy Patient conversion from older therapies, particularly eculizumab, significantly drives ULTOMIRIS growth. Over 70% of PNH patients have transitioned to ULTOMIRIS, with more than 60% of newly diagnosed PNH patients in Europe starting with this therapy, strengthening AstraZeneca's market hold while enhancing patient outcomes. Expanding Regulatory Approvals Across Multiple Rare Diseases ULTOMIRIS has moved beyond hematology to cover neurology and nephrology, securing approvals for conditions like PNH, aHUS, gMG, and NMOSD. The 2024 FDA approval for NMOSD, based on the CHAMPION-NMOSD trial, highlights zero relapses over a 73-week follow-up, expanding the patient base significantly. Growing Complement-Mediated Disease Market Increasing recognition of complement pathway disorders as rare autoimmune disease drivers is expanding the treatable population for ULTOMIRIS. Rising diagnosis rates and enhanced clinical guidelines contribute to sustained demand across various disorders. Strong Commercial Performance and Rapid Revenue Growth Since its launch, ULTOMIRIS has seen robust commercial growth, with U.S. sales reaching $1.03 billion in the first half of 2024, up 27% from the past year. In its domain, it contributed 21% to growth in the hematological disorders market in 2023. Scope of the ULTOMIRIS Market Report ULTOMIRIS Competitive Landscape and Revenue Forecast ULTOMIRIS Market Report Highlights Key Topics Covered: 1. Report Introduction 2. ULTOMIRIS Overview in approved indications like PNH, Haemolytic uraemic syndrome, Myasthenia gravis; as well as potential indications like Acute kidney injury, Delayed graft function, IgA nephropathy, Thrombotic microangiopathies 2.1. Product Detail 2.2. ULTOMIRIS Clinical Development 2.2.1. ULTOMIRIS Clinical studies 2.2.2. ULTOMIRIS Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. ULTOMIRIS Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging ULTOMIRIS Therapies) 5. ULTOMIRIS Market Assessment 5.1. ULTOMIRIS Market Outlook in approved and potential indications 5.2. 7MM Analysis 5.2.1. ULTOMIRIS Market Size in the 7MM for approved and potential indications 5.3. Country-wise Market Analysis 5.3.1. ULTOMIRIS Market Size in the United States for approved and potential indications 5.3.2. ULTOMIRIS Market Size in Germany for approved and potential indications 5.3.3. ULTOMIRIS Market Size in France for approved and potential indications 5.3.4. ULTOMIRIS Market Size in Italy for approved and potential indications 5.3.5. ULTOMIRIS Market Size in Spain for approved and potential indications 5.3.6. ULTOMIRIS Market Size in the United Kingdom for approved and potential indications 5.3.7. ULTOMIRIS Market Size in Japan for approved and potential indications 6. ULTOMIRIS SWOT Analysis 7. Analysts' Views 8. Appendix For more information about this report visit https://www.researchandmarkets.com/r/qt885j About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View stock analysis, news, and events for Alnylam Pharmaceuticals, Inc.